EMA Recommends Granting a Marketing Authorisation for Aumolertinib By Ogkologos - January 8, 2026 530 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of patients with EGFR-mutated NSCLC Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR FDA Approves Idecabtagene Vicleucel for Multiple Myeloma April 7, 2021 Cancer Surgery Unexpectedly Canceled for Mother of Two, Who Says It’s... March 31, 2020 ESMO Immuno-Oncology Congress 2023, 6-8 December 2023, Geneva, Switzerland November 29, 2023 Zucchini everywhere October 9, 2020 Load more HOT NEWS Adjuvant Atezolizumab Plus Bevacizumab Improves RFS Among Patients at High Risk... From athlete to wig-maker: how cancer changed Maria’s destiny ACS’s Updated Cervical Cancer Screening Guidelines Explained FDA Approves Idecabtagene Vicleucel for Multiple Myeloma
